Taylor, GP;
Goon, P;
Furukawa, Y;
Green, H;
Barfield, A;
Mosley, A;
Nose, H;
... Weber, JN; + view all
(2006)
Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial.
Retrovirology
, 3
, Article 63. 10.1186/1742-4690-3-63.
![[thumbnail of Taylor_Zidovudine_2006_1742-4690-3-63.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
Taylor_Zidovudine_2006_1742-4690-3-63.pdf Download (288kB) |
Abstract
Background: No therapies have been proven to persistently improve the outcome of HTLV-1-associated myelopathy. Clinical benefit has been reported with zidovudine and with lamivudine in observational studies. We therefore conducted a randomised, double blind, placebo controlled study of six months combination therapy with these nucleoside analogues in sixteen patients. Results: Primary outcomes were change in HTLV-1 proviral load in PBMCs and clinical measures. Secondary endpoints were changes in T-cell subsets and markers of activation and proliferation. Six patients discontinued zidovudine. No significant changes in pain, bladder function, disability score, gait, proviral load or markers of T-cell activation or proliferation were seen between the two arms. Active therapy was associated with an unexplained decrease in CD8 and non-T lymphocyte counts. Conclusion: Failure to detect clinical improvement may have been due irreversible nerve damage in these patients with a long clinical history and future studies should target patients presenting earlier. The lack of virological effect but may reflect a lack of activity of these nucleoside analogues against HTLV-1 RT in vivo, inadequate intracellular concentrations of the active moiety or the contribution of new cell infection to maintaining proviral load at this stage of infection may be relatively small masking the effects of RT inhibition.
| Type: | Article |
|---|---|
| Title: | Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/1742-4690-3-63 |
| Publisher version: | http://dx.doi.org/10.1186/1742-4690-3-63 |
| Language: | English |
| Additional information: | © 2006 Taylor et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | Blood mononuclear-cells, Tropical spastic paraparesis, Central-nervous-system, HTLV-I, Peripheral-blood, Reverse-transcriptase, Leukemia, Infection, Transmission, Replication |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Institute of Prion Diseases UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Institute of Prion Diseases > MRC Prion Unit at UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/118124 |
Archive Staff Only
 |
View Item |
